NasdaqGM:SESN

Stock Analysis Report

Executive Summary

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Sesen Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SESN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.2%

SESN

2.0%

US Biotechs

-2.8%

US Market


1 Year Return

-48.6%

SESN

-1.3%

US Biotechs

-15.9%

US Market

Return vs Industry: SESN underperformed the US Biotechs industry which returned -0.9% over the past year.

Return vs Market: SESN underperformed the US Market which returned -15.1% over the past year.


Shareholder returns

SESNIndustryMarket
7 Day-8.2%2.0%-2.8%
30 Day-39.5%-8.0%-18.8%
90 Day-49.4%-4.6%-24.0%
1 Year-48.6%-48.6%-0.5%-1.3%-14.2%-15.9%
3 Year-73.8%-73.8%13.3%10.5%9.9%2.8%
5 Year-95.0%-95.0%-7.7%-12.0%27.2%13.3%

Price Volatility Vs. Market

How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sesen Bio undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SESN ($0.52) is trading below our estimate of fair value ($24.2)

Significantly Below Fair Value: SESN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SESN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SESN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SESN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SESN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Sesen Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

58.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SESN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SESN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sesen Bio performed over the past 5 years?

-25.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SESN is currently unprofitable.

Growing Profit Margin: SESN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SESN is unprofitable, and losses have increased over the past 5 years at a rate of -25.6% per year.

Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SESN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Sesen Bio's financial position?


Financial Position Analysis

Short Term Liabilities: SESN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SESN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SESN is debt free.

Reducing Debt: SESN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: SESN has a low level of unsold assets or inventory.

Debt Coverage by Assets: SESN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SESN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SESN has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -1.1% each year.


Next Steps

Dividend

What is Sesen Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SESN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Thomas Cannell (57yo)

1.67s

Tenure

US$2,009,874

Compensation

Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD2.01M) is above average for companies of similar size in the US market ($USD618.59K).

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Cannell
President1.67yrsUS$2.01mno data
Dennis Kim
Chief Medical Officer1.33yrsUS$709.28k0.018% $10.4k
Gregory Verdine
Co-Founderno datano datano data
Monica Forbes
Chief Financial Officer0.67yrno datano data
Kirstin Anderson
Corporate Controller & Principal Accounting Officer0.67yrno data0.029% $16.7k
Glen MacDonald
Chief Technology Officer3.17yrsno datano data
Erin Clark
Vice President of Corporate Strategy & Investor Relationsno datano datano data
Mark Sullivan
General Counsel & Corporate Secretary0.67yrno datano data
David Brooks
Senior Vice President of Clinical Development2.92yrsno datano data
Jeannick Cizeau
Head of Researchno datano datano data

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: SESN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thomas Cannell
President1.67yrsUS$2.01mno data
Daniel Lynch
Independent Director6.17yrsUS$130.30k0.032% $18.1k
Neal Shore
Member of Medical Advisory Boardno datano datano data
Jane Pritchett Henderson
Independent Director6.17yrsUS$133.43kno data
Jay Duker
Independent Chairman of the Board0.17yrUS$113.78kno data
Michael Jewett
Member of Medical Advisory Boardno datano datano data
Carrie Bourdow
Independent Director0.17yrno data0.0030% $1.7k
Jason Keyes
Independent Director0.17yrno data0.0030% $1.7k
Rian Dickstein
Member of Medical Advisory Boardno datano datano data
Thomas Keane
Member of Medical Advisory Boardno datano datano data

0.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: SESN's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.2%.


Top Shareholders

Company Information

Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sesen Bio, Inc.
  • Ticker: SESN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$57.084m
  • Shares outstanding: 109.99m
  • Website: https://www.sesenbio.com

Number of Employees


Location

  • Sesen Bio, Inc.
  • 245 First Street
  • Suite 1800
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SESNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
PCBKDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014
0IFZLSE (London Stock Exchange)YesCommon StockGBUSDFeb 2014

Biography

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 13:08
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.